Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The placebo arm was switched to GH treatment from month 6 to month 12 (open phase), and a follow-up period after GH discontinuation was performed until month 18.

Standard treatment for fibromyalgia (selective serotonin re-uptake inhibitors, opioids, and amitriptyline) was maintained throughout the study.

Who Took Part

The study group was 120 patients.

PubMed indexes the participants as young adults, adults and middle-aged adults, women only.

How the Study Was Run

The researchers set it up as a randomized, placebo-controlled and multicenter study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

A placebo (an inactive look-alike) gave the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group a baseline to be compared against.

More than one site took part, so the patients came from several places.

What Was Measured

The subject headings attached to it are Fibromyalgia, Growth Hormone, Pain, Pain Measurement and Quality of Life.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 120 patients.

The publication is from 2012 (Pain), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.